FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a compound of formula (Ib) or a pharmaceutically acceptable salt thereof, in which R5 is selected from the group consisting of H and methyl, R6 is optionally substituted C6-C12 aryl, R is H or optionally substituted C1-C6 alkyl; R13 in each instance is independently selected from the group consisting of H, optionally substituted phenyl and optionally substituted benzyl, n is an integer selected from the group consisting of 1, 2, 3, 4 and 5, and m is an integer selected from the group, including 0, 1, 2 and 3, where the optional substituents are selected from the group consisting of halogen, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, -OH, phenyl, benzyl, phenoxy, benzyloxy, benzoyl, silyl, -NH2, -NHC1-4 alkyl, -N(C1-4 alkyl)2, -CN, -NO2, mercapto, P=O(OH)(NH2), -S(O)2NH2, -S(O)2 NHC1-4 alkyl, -S(O)2 N(C1-4 alkyl)2, C1-6 alkylcarbonyl, C1-6 alkoxycarbonyl, CO2H, -S(O)R-, where R is lower alkyl or cycloalkyl, and -S(O)2R-, where R is lower alkyl , cycloalkyl or OH, where the term "lower alkyl" refers to alkyl groups containing from one to six carbon atoms. The invention relates to specific compounds (shown in the claims). The invention also relates to a pharmaceutical composition for treating or preventing a disease or disorder associated with mitochondrial dysfunction, comprising a therapeutically effective amount of a compound of the invention. The compounds of the invention are used for the treatment or prevention of a disease or disorder associated with mitochondrial dysfunction, which is selected from the group consisting of Leber hereditary optic neuropathy (LHON), diabetic retinopathy, ulcerative colitis (UC).
(Ib)
EFFECT: compounds applicable for the prevention and/or treatment of diseases and disorders associated with mitochondrial dysfunction.
11 cl, 9 tbl, 11 dwg, 26 ex
| Title | Year | Author | Number |
|---|---|---|---|
| INHIBITORS - AMINO - CARBOXYMUCONATE - SEMIALDEHYDE - DECARBOXYLASE | 2015 |
|
RU2746405C2 |
| α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE INHIBITORS | 2019 |
|
RU2841136C2 |
| BISPHENOL DERIVATIVES AND THEIR USE AS ACTIVITY MODULATORS OF ANDROGEN RECEPTOR | 2017 |
|
RU2767257C2 |
| IMIDAZOPYRIDINE DERIVATIVE AND PHARMACEUTICAL PREPARATION CONTAINING IT AS AN ACTIVE INGREDIENT | 2020 |
|
RU2810973C2 |
| PURINONE COMPOUNDS AS KINASE INHIBITORS | 2013 |
|
RU2655388C2 |
| FIBROBLAST ACTIVATION PROTEIN INHIBITORS | 2020 |
|
RU2802426C2 |
| NEW SULPHONAMIDE DERIVATIVES WITH SELECTIVE NOX INHIBITORY ACTIVITY | 2019 |
|
RU2809030C2 |
| 1,3,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE 6 INHIBITOR AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | 2019 |
|
RU2763936C1 |
| COMPOUNDS USABLE FOR THE TREATMENT OF RESPIRATORY DISEASE IN CATTLE OR PIGS | 2017 |
|
RU2775529C2 |
| ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | 2019 |
|
RU2797622C2 |
